The serious complications of GLP-1s that few may know about
The U.S. Food and Drug Administration has ordered manufacturers to add a warning about a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) to the labels of roughly a dozen GLP-1 receptor agonists. The requirement covers widely used diabetes and weight-loss medications such as Novo Nordisk's Ozempic and Wegovy (semaglutide) and Eli Lilly's Zepbound and Mounjaro (tirzepatide). The agency said the condition can cause sudden vision loss and that patients should be advised to seek immediate medical attention if visual changes occur.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ FDA ordered a new warning about non-arteritic anterior ischemic optic neuropathy (NAION) on the labels of about a dozen GLP-1 receptor agonist drugs.
- ✓ The affected drugs include Novo Nordisk's Ozempic and Wegovy (semaglutide) and Eli Lilly's Zepbound and Mounjaro (tirzepatide).
- ✓ NAION can cause sudden, potentially permanent vision loss and patients are advised to seek immediate medical care if vision changes occur.
What changed
FDA issued a class-wide labeling update requiring a NAION warning on approximately 12 GLP-1 products, expanding safety monitoring beyond previously listed risks.
Live updates
-
FDA mandates new eye-risk warning on GLP-1 drugs including Ozempic, Wegovy, Zepbound
The U.S. Food and Drug Administration has ordered manufacturers to add a warning about a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) to the labels of roughly a dozen GLP-1 receptor agonists. The requirement covers widely used diabetes and weight-loss medications such as Novo Nordisk's Ozempic and Wegovy (semaglutide) and Eli Lilly's Zepbound and Mounjaro (tirzepatide). The agency said the condition can cause sudden vision loss and that patients should be advised to seek immediate medical attention if visual changes occur.
Why it matters
GLP-1 drugs have become some of the most prescribed medications in the United States, with tens of millions of prescriptions written for diabetes and obesity. Until now, labeling focused on gastrointestinal side effects, pancreatitis, and thyroid-tumor risk. The new mandate reflects accumulating post-marketing reports linking the drug class to NAION, a stroke-like event in the optic nerve that can leave permanent vision impairment. Regulators emphasized that the overall benefit-risk profile remains favorable for approved indications.
What is confirmed
- FDA ordered a new warning about non-arteritic anterior ischemic optic neuropathy (NAION) on the labels of about a dozen GLP-1 receptor agonist drugs.
- The affected drugs include Novo Nordisk's Ozempic and Wegovy (semaglutide) and Eli Lilly's Zepbound and Mounjaro (tirzepatide).
- NAION can cause sudden, potentially permanent vision loss and patients are advised to seek immediate medical care if vision changes occur.
Still unconfirmed
- A Washington Post anecdote describes a patient who lost vision in one eye four months after starting Ozempic, with the ophthalmologist unable to identify a cause at the time.
What to watch next
- Publication of FDA's official safety communication and updated prescribing information for each product
- Analysis of post-marketing surveillance data to quantify NAION incidence rates relative to background
- Potential label updates in other major regulatory jurisdictions (EMA, Health Canada, PMDA)
confidence 93%Sources used for this update (14)
- hotair.com — HotAir - Politics, Culture, Media, Breaking News from a conservative ...
- www.yahoo.com — Yahoo
- www.iheart.com — ONE THIRD OF TRUMP '24 VOTERS ABANDON HIM AS MIDTERMS LOOM -10.12.26
- www.wbur.org — ICE wants robot dogs. Boston Dynamics' workers urge company to 'cancel the sale'
- www.spokesman.com — As missiles hit Saudi Arabia, residents insist life goes on — and the show does too
- www.nzherald.co.nz — The four most revealing insights from Netflix’s new Matthew Perry doc
- The Washington Post — The serious complications of GLP-1s that few may know about
- Fast Company — Taking Ozempic or Wegovy? The FDA says there’s a new warning you shouldn’t ignore
- CNBC — FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
- Fierce Pharma — FDA orders new eye risk be listed on a dozen GLP-1s, including Novo's Ozempic, Lilly's Zepbound
- Yahoo — FDA requires warning on GLP-1 drugs over rare eye condition
- www.realclearpolitics.com — Generation COVID: The Collateral Damage
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community